TY - JOUR
T1 - Antiviral and antibacterial properties of phloroglucinols
T2 - a review on naturally occurring and (semi)synthetic derivatives with potential therapeutic interest
AU - Peron, Gregorio
AU - López, Alice M.
AU - Cabada-Aquirre, Paulina
AU - Garay Buenrosto, Karen D.
AU - Ostos Mendoza, Keila C.
AU - Mahady, Gail B.
AU - Seidel, Veronique
AU - Sytar, Oksana
AU - Koirala, Niranjan
AU - Gurung, Roshani
AU - Acharya, Zenisha
AU - Adhikari, Sundar
AU - Sureda, Antoni
AU - Martorell, Miquel
AU - Sharifi-Rad, Javad
PY - 2024/2/17
Y1 - 2024/2/17
N2 - Phloroglucinol and derived compounds comprise a huge class of secondary metabolites widely distributed in plants and brown algae. A vast array of biological activities, including antioxidant, anti-inflammatory, antimicrobial, and anticancer has been associated to this class of compounds. In this review, the available data on the antiviral and antibacterial capacity of phloroglucinols have been analyzed. Some of these compounds and derivatives show important antimicrobial properties in vitro. Phloroglucinols have been shown to be effective against viruses, such as human immunodeficiency virus (HIV), herpes or enterovirus, and preliminary data through docking analysis suggest that they can be effective against SARS-CoV-19. Also, some phloroglucinols derivatives have shown antibacterial effects against diverse bacteria strains, including Bacillus subtilis and Staphylococcus aureus, and (semi)synthetic development of novel compounds have led to phloroglucinols with a significantly increased biological activity. However, therapeutic use of these compounds is hindered by the absence of in vivo studies and scarcity of information on their mechanisms of action, and hence further research efforts are required. On the basis of this consideration, our work aims to gather data regarding the efficacy of natural-occurring and synthetic phloroglucinol derivatives as antiviral and antibacterial agents against human pathogens, which have been published during the last three decades. The recollection of results reported in this review represents a valuable source of updated information that will potentially help researchers in the development of novel antimicrobial agents.
AB - Phloroglucinol and derived compounds comprise a huge class of secondary metabolites widely distributed in plants and brown algae. A vast array of biological activities, including antioxidant, anti-inflammatory, antimicrobial, and anticancer has been associated to this class of compounds. In this review, the available data on the antiviral and antibacterial capacity of phloroglucinols have been analyzed. Some of these compounds and derivatives show important antimicrobial properties in vitro. Phloroglucinols have been shown to be effective against viruses, such as human immunodeficiency virus (HIV), herpes or enterovirus, and preliminary data through docking analysis suggest that they can be effective against SARS-CoV-19. Also, some phloroglucinols derivatives have shown antibacterial effects against diverse bacteria strains, including Bacillus subtilis and Staphylococcus aureus, and (semi)synthetic development of novel compounds have led to phloroglucinols with a significantly increased biological activity. However, therapeutic use of these compounds is hindered by the absence of in vivo studies and scarcity of information on their mechanisms of action, and hence further research efforts are required. On the basis of this consideration, our work aims to gather data regarding the efficacy of natural-occurring and synthetic phloroglucinol derivatives as antiviral and antibacterial agents against human pathogens, which have been published during the last three decades. The recollection of results reported in this review represents a valuable source of updated information that will potentially help researchers in the development of novel antimicrobial agents.
KW - algae
KW - antimicrobials
KW - phloroglucinol
KW - SARS CoV-19
KW - semisynthesis
U2 - 10.1080/07388551.2022.2160695
DO - 10.1080/07388551.2022.2160695
M3 - Article
SN - 0738-8551
VL - 44
SP - 319
EP - 336
JO - Critical Reviews in Biotechnology
JF - Critical Reviews in Biotechnology
IS - 2
ER -